Table 3 Correlation of EGFR mutations with clinicopathological features of NSCLC patients

Male

334 (67.61)

108 (32.34)

226 (67.66)

Ref.

Ref.

Female

160 (32.39)

68 (42.50)

92 (57.50)

1.55 (1.05–2.28)

0.028

0.64 (0.32–1.28)

0.209

≤65

271 (54.86)

122 (45.02)

149 (54.98)

2.56 (1.73–3.78)

<0.001

2.51 (1.65–3.81)

<0.001

>65

223 (45.14)

54 (24.22)

169 (75.78)

Ref.

Ref.

Ever smoker

348 (70.45)

102 (29.31)

246 (70.69)

Ref.

Ref.

Never smoker

146 (29.55)

74 (50.68)

72 (49.32)

2.48 (1.66–3.69)

<0.001

3.63 (1.83–7.19)

<0.001

Male

21 (14.38)

11 (52.38)

10 (47.62)

Ref.

Female

125 (85.62)

63 (50.40)

62 (49.60)

0.92 (0.37–2.33)

0.867

I + II

171 (34.62)

55 (32.16)

116 (67.84)

Ref.

Ref.

III + IV

323 (65.38)

121 (37.46)

202 (62.54)

1.26 (0.85–1.87)

0.243

1.45 (0.94– 2.24)

0.089

Non-ADC

184 (32.75)

35 (19.02)

149 (80.98)

Ref.

Ref.

ADC

310 (62.75)

141 (45.48)

169 (54.52)

3.55 (2.31–5.46)

<0.001

3.57 (2.28–5.61)

<0.001

Male

212 (68.39)

86 (40.57)

126 (59.43)

Ref.

Female

98 (31.61)

55 (56.12)

43 (43.88)

1.87 (1.15–3.04)

0.011

Male

15 (16.13)

9 (60.00)

6 (40.00)

Ref.

Female

78 (83.87)

51(65.38)

27(34.62)

1.26 (0.41–3.91)

0.69

Well

145 (29.35)

50 (34.48)

95 (65.52)

Ref.

Ref.

Moderate

249 (50.40)

92 (36.95)

157 (63.05)

1.11 (0.73–1.71)

0.623

1.14 (0.72–1.82)

0.573

Poor

97 (19.64)

34 (35.05)

63 (64.95)

1.03 (0.60–1.76)

0.927

1.10 (0.60–2.00)

0.759